Lupus Nephritis

Lupus nephritis is a kidney disease caused by systemic lupus erythematosus, an autoimmune disease.

Quick Answer

What it is

Lupus nephritis is a kidney disease caused by systemic lupus erythematosus, an autoimmune disease.

Key findings

Grade A: Complete Renal Response (Voclosporin (Lupkynis))
Grade A: Response in High Proteinuria (Voclosporin (Lupkynis))
Grade A: Long-term Efficacy and Safety (Voclosporin (Lupkynis))

Safety

AURA-LV Phase 2: Higher adverse events including deaths in low-dose group (11.2% vs 2.3% high-dose vs 1.1% placebo) - led to dose selection refinement.

ℹ️ Quick Facts

Quick Facts: Lupus Nephritis

Supplements Studied:1

1 supps · 5 outcomes

Evidence-Based Protocol

Supplement stack ranked by research quality

Limited Evidence

How It Works

Research on supplement interventions for lupus nephritis remains limited, and no supplements have accumulated sufficient clinical evidence to warrant strong recommendations at this time. This does not mean that nutritional support is irrelevant to this condition, but rather that rigorous controlled trials have not yet established clear efficacy for specific supplements.

The underlying biology of lupus nephritis involves complex interactions between multiple physiological systems, including immune function, cellular signaling pathways, and metabolic regulation. While certain nutrients and botanical compounds show theoretical promise based on their known mechanisms of action, translating this potential into proven clinical benefits requires extensive research.

For individuals seeking to support their health while managing lupus nephritis, focusing on foundational wellness practices remains advisable. This includes maintaining adequate intake of essential vitamins and minerals through diet or a quality multivitamin, supporting gut health with fermented foods or probiotics, managing inflammation through omega-3 fatty acids, and ensuring sufficient vitamin D status.

Consulting with a healthcare provider who can evaluate individual nutritional status and recommend appropriate testing is the most prudent approach. As research continues to evolve, evidence-based supplement recommendations may emerge. Until then, prioritizing overall nutritional adequacy and conventional medical care represents the safest path forward.

Generated from peer-reviewed researchSchema v

Detailed Outcomes

Complete Renal Response

AURORA 1 Phase 3 (n=357): Complete renal response at 52 weeks 40.8% voclosporin vs 22.5% placebo (OR 2.7; 95% CI 1.6-4.3; P<0.001). Added to MMF + low-dose steroids. UPCR ≤0.5 mg/mg: 45.3% vs 23.0% (OR 3.1). Clinically and statistically superior.

large↑Improves

Response in High Proteinuria

Subgroup with UPCR ≥3 g/g (n=148): Complete renal response 34% voclosporin vs 11% control at 12 months (OR 4.43; 95% CI 1.78->9.99; P=0.001). Greater benefit in patients with higher baseline proteinuria.

large↑Improves

Long-term Efficacy and Safety

AURORA 2 extension (n=216): 86.1% completed 3-year study. Treatment well-tolerated with no unexpected safety signals. Sustained efficacy over long-term follow-up. No new safety concerns identified.

moderate↓Worsens

Hypertension Risk

SAFETY: New-onset or worsening hypertension common with calcineurin inhibitors. Blood pressure monitoring required. Consider antihypertensive therapy. May require dose adjustment or discontinuation if uncontrolled.

moderate↑Worsens

Nephrotoxicity Risk

SAFETY: Acute and chronic nephrotoxicity possible. Monitor eGFR regularly. Reduce dose if eGFR decreases. AURA-LV Phase 2: Higher adverse events including deaths in low-dose group (11.2% vs 2.3% high-dose vs 1.1% placebo) - led to dose selection refinement.

moderate↑Worsens